Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma

Status:
RECRUITING

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Phase I open-label trial of 123I-ATT001 monotherapy and in combination with treatment therapies in subjects with relapsed glioblastoma.

PHASE1

Theragnostics Ltd